Relapsed or refractory primary mediastinal B-Cell lymphoma – pembrolizumab initial PBS authority application form (PB296)

Use this form to apply for initial Pharmaceutical Benefits Scheme (PBS) subsidised treatment with pembrolizumab for relapsed or refractory mediastinal B-Cell lymphoma.